Generalized lymphadenopathy as the first manifestation of metastatic malignant melanoma: a diagnostic paradox
Keywords:
malignant melanoma, melanoma of unknown primary, lymph node metastasis, immunohistochemistryAbstract
Background: Although more than 90% of melanomas have cutaneous origin, there are a few cases who present with lymph node disease or metastatic viscera lesions, with no identifiable primary, described as melanomas of unknown primary site.
Case Report: We report a case of a morbidly obese 63-year-old male, with multiple comorbidities, who presented with neurological symptoms and extensive lymphadenopathy was revealed on clinical examination and on imaging. Excisional biopsy of a supraclavicular nodal mass followed and histopathological examination with the aid of immunohistochemistry lead to the diagnosis of metastatic malignant melanoma. Despite investigations the primary tumor site remained unrevealed and the patient received palliative chemotherapy.
Discussion: Generally, melanomas evolve from any site of the body containing melanocytes or cells that are capable of differentiating into melanocytes, although cases without an identifiable cutaneous, ocular, or mucosal primary, claimed as melanomas of unknown primary, comprise only 1-4% of melanoma cases per year. Extensive work-up sometimes seem meaningless. It is also stated that such patients with lymph nodal disease, despite the unfavorable sign of nodal involvement fare better survival rates than common patients with known primary and lymph nodal metastasis.
Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.